Next Century Growth Investors LLC Has $20.46 Million Stock Holdings in GeneDx Holdings Corp. $WGS

Next Century Growth Investors LLC lowered its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 46.9% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 221,610 shares of the company’s stock after selling 195,427 shares during the quarter. GeneDx comprises approximately 1.6% of Next Century Growth Investors LLC’s holdings, making the stock its 19th largest holding. Next Century Growth Investors LLC owned 0.77% of GeneDx worth $20,457,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. US Bancorp DE grew its stake in shares of GeneDx by 3,223.5% during the 1st quarter. US Bancorp DE now owns 565 shares of the company’s stock worth $50,000 after acquiring an additional 548 shares in the last quarter. AlphaQuest LLC lifted its stake in GeneDx by 351.5% in the 2nd quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after purchasing an additional 594 shares during the last quarter. PNC Financial Services Group Inc. bought a new position in GeneDx during the first quarter worth about $132,000. Ameritas Investment Partners Inc. increased its position in GeneDx by 61.0% during the second quarter. Ameritas Investment Partners Inc. now owns 1,917 shares of the company’s stock worth $177,000 after buying an additional 726 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC bought a new stake in GeneDx in the second quarter valued at approximately $204,000. 61.72% of the stock is currently owned by institutional investors.

GeneDx Trading Up 0.6%

NASDAQ:WGS opened at $160.82 on Wednesday. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87. The stock’s fifty day moving average price is $136.93 and its two-hundred day moving average price is $112.36. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. The company has a market cap of $4.65 billion, a P/E ratio of 1,786.89 and a beta of 1.99.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The company had revenue of $116.74 million for the quarter, compared to analyst estimates of $104.33 million. As a group, analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Insider Transactions at GeneDx

In other GeneDx news, Director Joshua Ruch sold 38,000 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $160.37, for a total value of $6,094,060.00. Following the completion of the sale, the director owned 11,941 shares of the company’s stock, valued at $1,914,978.17. This represents a 76.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $452,840.16. Following the completion of the sale, the chief financial officer owned 8,755 shares of the company’s stock, valued at approximately $1,063,469.85. The trade was a 29.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 54,775 shares of company stock valued at $8,170,087 in the last quarter. Insiders own 29.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on WGS shares. Canaccord Genuity Group set a $160.00 price target on GeneDx and gave the stock a “buy” rating in a report on Wednesday, October 29th. Zacks Research downgraded GeneDx from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 2nd. Wells Fargo & Company raised their price objective on GeneDx from $95.00 to $140.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 4th. BTIG Research boosted their price target on GeneDx from $140.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a report on Wednesday, October 8th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $129.22.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.